BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24755555)

  • 1. Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin.
    Yang F; Long W; Xuechuan H; Xueqin L; Hongyun M; Yonghui D
    BMB Rep; 2015 Jan; 48(1):30-5. PubMed ID: 24755555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
    Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
    Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
    Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
    Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
    BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
    Ren L; Xiao L; Hu J
    J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
    Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
    Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
    Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
    Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y; Zhou H; Yang S; Su D
    Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
    Jiang L; Luo RY; Yang J; Cheng YX
    Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
    Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
    Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.
    Chen Q; Qin R; Fang Y; Li H
    Cell Physiol Biochem; 2015; 36(3):956-65. PubMed ID: 26087719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.